AstraZeneca Reports Phase III Success For Dapagliflozin
October 02 2009 - 4:45AM
Dow Jones News
U.K. drug maker AstraZeneca PLC (AZN.LN) Friday said an
experimental diabetes medicine being jointly developed with
Bristol-Myers Squibb Co. (BMY) met its goals in a phase III
trial.
The Anglo-Swedish drug maker said treatment with dapagliflozin
led to a grreater reduction in blood sugar levels when given
alongside the common diabetes drug metformin compared to those
getting metformin and a placebo.
Company Web site: www.astrazeneca.com
-By Jason Douglas, Dow Jones Newswires; 44-20-7842-9272;
jason.douglas@dowjones.com